Theralase Presents Latest Research on Destruction of Cancer and Bacteria at International Conference

Toronto, Ontario -- October 16, 2014 / Theralase Technologies Inc. ("Theralase(R)") (TSXV: TLT) (TLTFF: OTC Link(R)) announced today that it has presented its latest research on the success of its Photo Dynamic Compounds ("PDCs") in the destruction of cancer and bacteria. This research was presented at the 10th International Symposium on Photodynamic Therapy and Photodiagnosis in Clinical Practice, taking place in Brixen, Italy from October 14 to 18, 2014.

Cancer remains one of the top human conditions and effective minimal or non-invasive treatments with low side effects and high success rates are urgently needed. Photo Dynamic Therapy ("PDT"), the combination of a Photo Dynamic Compound ("PDC") and a specific wavelength of light to produce cytotoxic (cell death) oxygen species, has been shown to be a promising avenue for cancer treatment.

Unilife Signs 15-Year Commercial Supply Agreement for Wearable Injectors with Sanofi

Unilife to be the sole provider of wearable injectors for all of Sanofi's applicable large dose volume drugs

YORK, Pa., Oct. 6, 2014 -- Unilife Corporation (NASDAQ: UNIS and ASX: UNS), a developer and supplier of injectable drug delivery systems, announced today the signing of a worldwide Master Services and Commercial Supply Agreement with Sanofi to be the sole provider of cartridge based wearable injectors for all of Sanofi's applicable large dose volume drugs, excluding insulins, for a minimum 15 years. Additionally the agreement will allow Sanofi to make Unilife's wearable injectors available to its partners for use with applicable molecules under joint collaborations.

Misonix, Inc. Announces Fourth Quarter and Fiscal Year End 2014 Financial Results

Fourth Quarter Net Revenues UP 48%;
BoneScalpel™Revenue UP 65%; SonaStar® Revenue up 75%; Fiscal Year Revenue Increased 15%;
Net Income of $1.4 million or $0.19 per Diluted Share

FARMINGDALE, N.Y., Sept. 10, 2014 -- Misonix, Inc. (MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, today announced financial results for the fourth quarter and full year fiscal 2014 ended June 30, 2014.

IMRIS neurosurgical HFD rocker arm receives FDA clearance

MINNEAPOLIS, Sept. 11, 2014 - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today announced a new rocker arm accessory that expands choices for neurosurgeons to select the best fixation suited for patients during procedures using intraoperative imaging inside the VISIUS Surgical Theatre. The accessory recently received 510(k) clearance from the U.S. Food and Drug Administration.

The new rocker arm accessory provides more flexibility for the surgeon to stabilize, support and position patient heads with varying cranial anatomy, sizes and conditions using the MRI-compatible IMRIS HFD. When attached to the head fixation device (HFD) - a clamp-like device - the rocker arm helps to reduce the pressure on the individual contact points on the patient's skull.

Hansen Medical Announces US Commercial Availability of Magellan(TM) Transport System

MOUNTAIN VIEW, CA--( Aug 27, 2014) - Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced it has received U.S. Food and Drug Administration 510(k) clearance for a modified rail for the Magellan™ Robotic System, which enables the company to begin commercial introduction of the Magellan™ Transport System. The Magellan Transport System is designed to move the Magellan robotic arm between procedure rooms. The Company anticipates commercialization of the Magellan Transport System in the third quarter of fiscal 2014.